Forget GLP-1 stocks, baldness drugs are Wall Street’s next goldmine
Fortune 41
Drugmakers and investors are pushing baldness drug candidates after new clinical results, sending Veradermics and Absci shares up sharply and lifting Cosmo on experimental male-hair-loss data. Cosmo plans to submit a new drug application to US regulators in the first quarter of 2027, with analysts expecting its stock could nearly double in the next 12 months. Investment focus shifts from GLP-1 obesity treatments toward cash-pay, out-of-pocket hair-loss medicines, with more companies and AI-designed candidates competing for approvals despite high development risk.